These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

481 related items for PubMed ID: 17412744

  • 1. The contribution of single antigen measles, mumps and rubella vaccines to immunity to these infections in England and Wales.
    Sonnenberg P, Crowcroft NS, White JM, Ramsay ME.
    Arch Dis Child; 2007 Sep; 92(9):786-9. PubMed ID: 17412744
    [Abstract] [Full Text] [Related]

  • 2. A serological survey of measles, mumps and rubella immunity among school aged children in Western Saudi Arabia.
    Jaber SM.
    Saudi Med J; 2006 Jan; 27(1):63-9. PubMed ID: 16432596
    [Abstract] [Full Text] [Related]

  • 3. The epidemiology of rubella in England and Wales before and after the 1994 measles and rubella vaccination campaign: fourth joint report from the PHLS and the National Congenital Rubella Surveillance Programme.
    Miller E, Waight P, Gay N, Ramsay M, Vurdien J, Morgan-Capner P, Hesketh L, Brown D, Tookey P, Peckham C.
    Commun Dis Rep CDR Rev; 1997 Feb 07; 7(2):R26-32. PubMed ID: 9046126
    [Abstract] [Full Text] [Related]

  • 4. Increased measles-mumps-rubella (MMR) vaccine uptake in the context of a targeted immunisation campaign during a measles outbreak in a vaccine-reluctant community in England.
    Le Menach A, Boxall N, Amirthalingam G, Maddock L, Balasegaram S, Mindlin M.
    Vaccine; 2014 Feb 26; 32(10):1147-52. PubMed ID: 24440207
    [Abstract] [Full Text] [Related]

  • 5. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.
    Lieberman JM, Williams WR, Miller JM, Black S, Shinefield H, Henderson F, Marchant CD, Werzberger A, Halperin S, Hartzel J, Klopfer S, Schödel F, Kuter BJ, Consistency Lot Study Group for ProQuad.
    Pediatr Infect Dis J; 2006 Jul 26; 25(7):615-22. PubMed ID: 16804432
    [Abstract] [Full Text] [Related]

  • 6. Why do parents hesitate to vaccinate their children against measles, mumps and rubella?
    Alfredsson R, Svensson E, Trollfors B, Borres MP.
    Acta Paediatr; 2004 Sep 26; 93(9):1232-7. PubMed ID: 15384890
    [Abstract] [Full Text] [Related]

  • 7. Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life.
    Schuster V, Otto W, Maurer L, Tcherepnine P, Pfletschinger U, Kindler K, Soemantri P, Walther U, Macholdt U, Douha M, Pierson P, Willems P.
    Pediatr Infect Dis J; 2008 Aug 26; 27(8):724-30. PubMed ID: 18600190
    [Abstract] [Full Text] [Related]

  • 8. Prevalence of IgG antibody against measles, mumps and rubella in bangladeshi children: a pilot study to evaluate the need for integrated vaccination strategy.
    Sultana R, Rahman MM, Hassan Z, Hassan MS.
    Scand J Immunol; 2006 Dec 26; 64(6):684-9. PubMed ID: 17083626
    [Abstract] [Full Text] [Related]

  • 9. Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella.
    Nascimento Silva JR, Camacho LA, Siqueira MM, Freire Mde S, Castro YP, Maia Mde L, Yamamura AM, Martins RM, Leal Mde L, Collaborative Group for the Study of Yellow Fever Vaccines.
    Vaccine; 2011 Aug 26; 29(37):6327-34. PubMed ID: 21640779
    [Abstract] [Full Text] [Related]

  • 10. Long-term immunogenicity of measles, mumps and rubella-containing vaccines in healthy young children: A 10-year follow-up.
    Carryn S, Feyssaguet M, Povey M, Di Paolo E.
    Vaccine; 2019 Aug 23; 37(36):5323-5331. PubMed ID: 31345639
    [Abstract] [Full Text] [Related]

  • 11. Long-term immunity to measles, mumps and rubella after MMR vaccination among children with bone marrow transplants.
    Spoulou V, Giannaki M, Vounatsou M, Bakoula C, Grafakos S.
    Bone Marrow Transplant; 2004 Jun 23; 33(12):1187-90. PubMed ID: 15077129
    [Abstract] [Full Text] [Related]

  • 12. The immunogenicity and reactogenicity of the trivalent vaccine, Trimovax, indicated for prevention of measles, mumps, and rubella, in 12-month-old children in Belarus.
    Samoilovich EO, Kapustik LA, Feldman EV, Yermolovich MA, Svirchevskaya AJ, Zakharenko DF, Fletcher MA, Titov LP.
    Cent Eur J Public Health; 2000 Aug 23; 8(3):160-3. PubMed ID: 10965439
    [Abstract] [Full Text] [Related]

  • 13. Assessment of humoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy.
    Zignol M, Peracchi M, Tridello G, Pillon M, Fregonese F, D'Elia R, Zanesco L, Cesaro S.
    Cancer; 2004 Aug 01; 101(3):635-41. PubMed ID: 15274078
    [Abstract] [Full Text] [Related]

  • 14. Measles, mumps and rubella: control by vaccination.
    van Druten JA, de Boo T, Plantinga AD.
    Dev Biol Stand; 1986 Aug 01; 65():53-63. PubMed ID: 3556777
    [Abstract] [Full Text] [Related]

  • 15. [Measles, mumps and rubella: vaccination rate and seroprevalence in 8th grade students of 8 different sites in Switzerland 1995/96].
    Stohrer-Draxl P, Amstad H, Grize L, Gassner M, Takken-Sahli K, Bourquin C, Braun-Fahrländer C.
    Praxis (Bern 1994); 1999 Jun 10; 88(24):1069-77. PubMed ID: 10420798
    [Abstract] [Full Text] [Related]

  • 16. Measles, Mumps, and Rubella Serostatus and Response to MMR Vaccination Among HIV-Infected Adults.
    Singh HK, Chiu YL, Wilkin T.
    AIDS Patient Care STDS; 2015 Sep 10; 29(9):461-4. PubMed ID: 26153909
    [No Abstract] [Full Text] [Related]

  • 17. Assessment of the potency and potential immunomodulatory effects of the measles mumps rubella and varicella vaccine in infants.
    Yerkovich ST, Rowe J, Richmond P, Suriyaarachchi D, Heaton T, Hollams E, Ladyman C, Serralha M, Sadowska A, Loh R, Wesselingh SL, Sly PD, Holt PG.
    Vaccine; 2007 Feb 26; 25(10):1764-70. PubMed ID: 17224218
    [Abstract] [Full Text] [Related]

  • 18. Comparison of vaccination with measles-mumps-rubella vaccine at 9, 12, and 15 months of age.
    Redd SC, King GE, Heath JL, Forghani B, Bellini WJ, Markowitz LE.
    J Infect Dis; 2004 May 01; 189 Suppl 1():S116-22. PubMed ID: 15106100
    [Abstract] [Full Text] [Related]

  • 19. Extinction of the human leukocyte antigen homozygosity effect after two doses of the measles-mumps-rubella vaccine.
    St Sauver JL, Dhiman N, Ovsyannikova IG, Jacobson RM, Vierkant RA, Pankratz VS, Jacobsen SJ, Poland GA.
    Hum Immunol; 2005 Jul 01; 66(7):788-98. PubMed ID: 16112026
    [Abstract] [Full Text] [Related]

  • 20. [Morbidity, vaccine coverage and immunity against measles, mumps and rubella in a Gallician population from 2 to 5 years old].
    Vázquez Fernández E, López Rois F, Vázquez Carrete JA, Gómez Tato B, Alvarez Ares M.
    An Esp Pediatr; 1987 Jul 01; 27(1):27-31. PubMed ID: 3662251
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.